Clinical trial QuANTUM-Wild
A Phase 3, Double-Blind, Placebo-Controlled Study of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in adult patients with newly diagnosed FLT3-ITD (-) Acute Myeloid Leukemia
| Cancers | |
|---|---|
| Organ | Acute leukemia |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Daiichi Sankyo |
| EudraCT Identifier | 2023-507936-20-00 |
| Inclusion criteria | Participants must satisfy all of the following criteria to be randomized:1. Must be competent and able to comprehend, sign, and date an Ethics Committee (EC)-or Institutional Review Board (IRB)-approved Informed Consent Form (ICF) beforeperformance of |
| Last update |